Home/Pipeline/Fragile X Program

Fragile X Program

Fragile X Syndrome

PreclinicalActive

Key Facts

Indication

Fragile X Syndrome

Phase

Preclinical

Status

Active

Company

Sentinel Oncology

About Sentinel Oncology

Sentinel Oncology is a private, preclinical-stage biotech company leveraging its medicinal chemistry expertise to develop targeted small molecule inhibitors for cancers with high unmet need, especially those affecting the brain. Its pipeline features three late-stage preclinical programs, with its lead asset, SOL578 (a Chk1 inhibitor), having entered Phase 1 trials in 2023 via a licensing agreement with PharmaEngine. The company employs a collaborative business model, partnering with pharmaceutical and biotech organizations to advance and commercialize its programs.

View full company profile

Therapeutic Areas

Oncology Rare Neurological Disorders

Other Fragile X Syndrome Drugs

Drug	Company	Phase	Status
KER-0193	Kaerus Bioscience	Preclinical	Active
p70 S6 Kinase Inhibitor	Epigen Biosciences	Preclinical	Active
HLX-0206	Healx	AI Discovery	Active
ENT-3379	Enthorin Therapeutics	Phase 1	Active
AUT00206	Autifony Therapeutics	Clinical	Active
Fragile X Syndrome Program	Purposeful	Discovery/Pre-clinical	Active
Fragile X Syndrome Trial	Science 37	Phase 3	Completed/Highlighted
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Phase 2	Completed
Fragile X Syndrome Test	Genomics BioSci & Tech	Clinical	Active
Xanamem (emestedastat)	Actinogen Medical	Phase 2	Active